Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Illumina, Inc.NASDAQ: ILMN
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $60M (cash outflow) fell 17.8% year over year, ahead of the -56.8% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -9.1% a year.
Context
- Stock-based compensation amounted to 6.3% of revenue in FY2025, down 2.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -17.8% holds above the trailing-twelve-month pace of -56.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 275M USD
- Year-over-year change
- -25.7%
- 4-year CAGR
- -22.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 275M | -25.7% |
| FY2024 | 2024-12-29 | 370M | -2.6% |
| FY2023 | 2023-12-31 | 380M | +3.8% |
| FY2022 | 2023-01-01 | 366M | -51.5% |
| FY2021 | 2022-01-02 | 754M | — |
Stock-Based Compensation vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 stock-based compensation of $70M is the 4th largest of the 11 companies compared; the peer median is $30.18M.
- Its year-over-year change of -56.8% is the 9th highest of 10, against a peer median of -20.9%.
- Stock-based compensation amounts to 1.6% of revenue for ILMN, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $381.42M | +21.6% | +32.5% | 14.1% | |
| LTM Sep 2026 | $210.96M | +32.4% | +20.6% | 16.5% | |
| LTM Jun 2026 | $98.74M | -20.9% | -7.3% | 16.0% | |
| LTM Jun 2026 | $70M | -56.8% | -9.1% | 1.6% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $35.7M | +95.3% | -8.5% | 7.9% |
| LTM Mar 2026 | $32.2M | -31.9% | -2.6% | 3.9% | |
| LTM Jun 2026 | $28.16M | -29.2% | +18.8% | 3.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $25.54M | — | — | 6.4% |
| LTM Mar 2026 | $9.76M | -4.5% | -21.4% | 15.1% | |
| LTM Mar 2026 | $9.59M | -84.2% | -19.1% | 6.0% | |
| LTM Mar 2026 | $8.5M | -48.8% | — | 10.5% | |
| Peer median (excluding ILMN) | $30.18M | -20.9% | -4.9% | 9.2% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| Deferred Income Tax | (76M) | (23M) | (33M) | (112M) | 119M |
| Stock-Based Compensation | 754M | 366M | 380M | 370M | 275M |
| Change in Working Capital | (152M) | 204M | (90M) | (483M) | (153M) |
| Accounts Receivables | (164M) | (12M) | (40M) | (25M) | (108M) |
| Inventory | (58M) | (135M) | (20M) | 19M | (17M) |
| Accounts Payables | 60M | (38M) | (44M) | (4M) | 2M |
| Other Working Capital | 10M | 389M | 14M | (473M) | (30M) |
| Other Non-Cash Items | (994M) | 3.86B | 950M | 1.93B | (282M) |
| Operating Cash Flow | 545M | 392M | 478M | 837M | 1.08B |
| Capital Expenditures | (208M) | (286M) | (195M) | (128M) | (148M) |
| Acquisitions (Net) | (2.44B) | (265M) | (29M) | 2M | (10M) |
| Purchases of Investments | (77M) | (40M) | (6M) | (52M) | 0 |
| Sales of Investments | 1.66B | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | 103M |
| Investing Cash Flow | (1.07B) | (591M) | (231M) | (178M) | (55M) |
| Debt Repayment | 471M | 991M | (1.24B) | 491M | (5M) |
| Common Stock Issued | 60M | 63M | 67M | 56M | 44M |
| Common Stock Repurchased | 0 | 0 | 0 | (116M) | (742M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (582M) | (54M) | (42M) | (1B) | (41M) |
| Financing Cash Flow | (51M) | 1B | (1.21B) | (570M) | (744M) |
| Effect of Forex Changes | (3M) | (22M) | 0 | (10M) | 11M |
| Net Change in Cash | (578M) | 779M | (963M) | 79M | 291M |
| Free Cash Flow | 337M | 106M | 282M | 709M | 931M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.